Bispecific Antibody Cadonilimab Shows Survival Edge Over PD-1 Drugs in Gastric Cancer
A network meta-analysis of eight Phase III trials involving 7,127 patients suggests that the PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy ...
A network meta-analysis of eight Phase III trials involving 7,127 patients suggests that the PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine